9-hydroxy-β-dunnione | 1599459-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: 9-hydroxy-β-dunnione
• 英文别名: 9-hydroxy-2,3,3-trimethyl-2H-benzo[g][1]benzofuran-4,5-dione
• CAS: 1599459-29-6
• 化学式: C₁₅H₁₄O₄
• 分子量: 258.274
• InChiKey: NDNWQVVHBCSHSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  9-hydroxy-β-dunnione 在 盐酸 作用下， 以 水 为溶剂， 以100%的产率得到hydroxy-α-dunnione
  参考文献：
  名称：

  QSAR on antiproliferative naphthoquinones based on a conformation-independent approach

  摘要：

  The antiproliferative activities of a series of 36 naphthoquinone derivatives were subjected to a Quantitative Structure Activity Relationships (QSAR) study. For this purpose a panel of four human cancer cell lines was used, namely HBL-100 (breast), HeLa (cervix), SW-1573 (non-small cell lung) and WiDr (colon). A conformation-independent representation of the chemical structure was established in order to avoid leading with the scarce experimental information on X-ray crystal structure of the drug interaction. The 1179 theoretical descriptors derived with E-Dragon and Recon software were simultaneously analyzed through linear regression models based on the Replacement Method variable subset selection technique. The established models were validated and tested through the use of external test sets of compounds, the Leave-One-Out Cross Validation method, Y-Randomization and Applicability Domain analysis. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.02.057
• 作为产物：
  描述：

  甲烷磺酸 、 2,5-dihydroxy-3-(2-methylbut-3-en-2-yl)naphthalene-1,4-dione 以 二氯甲烷 为溶剂， 反应 0.05h， 以100%的产率得到9-hydroxy-β-dunnione
  参考文献：
  名称：

  QSAR on antiproliferative naphthoquinones based on a conformation-independent approach

  摘要：

  The antiproliferative activities of a series of 36 naphthoquinone derivatives were subjected to a Quantitative Structure Activity Relationships (QSAR) study. For this purpose a panel of four human cancer cell lines was used, namely HBL-100 (breast), HeLa (cervix), SW-1573 (non-small cell lung) and WiDr (colon). A conformation-independent representation of the chemical structure was established in order to avoid leading with the scarce experimental information on X-ray crystal structure of the drug interaction. The 1179 theoretical descriptors derived with E-Dragon and Recon software were simultaneously analyzed through linear regression models based on the Replacement Method variable subset selection technique. The established models were validated and tested through the use of external test sets of compounds, the Leave-One-Out Cross Validation method, Y-Randomization and Applicability Domain analysis. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.02.057

文献信息

• QSAR on antiproliferative naphthoquinones based on a conformation-independent approach
  作者：Pablo R. Duchowicz、Daniel O. Bennardi、Daniel E. Bacelo、Evelyn L. Bonifazi、Carla Rios-Luci、José M. Padrón、Gerardo Burton、Rosana I. Misico

  DOI：10.1016/j.ejmech.2014.02.057

  日期：2014.4

  The antiproliferative activities of a series of 36 naphthoquinone derivatives were subjected to a Quantitative Structure Activity Relationships (QSAR) study. For this purpose a panel of four human cancer cell lines was used, namely HBL-100 (breast), HeLa (cervix), SW-1573 (non-small cell lung) and WiDr (colon). A conformation-independent representation of the chemical structure was established in order to avoid leading with the scarce experimental information on X-ray crystal structure of the drug interaction. The 1179 theoretical descriptors derived with E-Dragon and Recon software were simultaneously analyzed through linear regression models based on the Replacement Method variable subset selection technique. The established models were validated and tested through the use of external test sets of compounds, the Leave-One-Out Cross Validation method, Y-Randomization and Applicability Domain analysis. (c) 2014 Elsevier Masson SAS. All rights reserved.